Evaluation of the CKD-EPI 2021 creatinine equation using laboratory data: Considerations for practice changes among clinical laboratories in British Columbia, Canada

IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Roy Yu-Wei Chen , Junyan Shi
{"title":"Evaluation of the CKD-EPI 2021 creatinine equation using laboratory data: Considerations for practice changes among clinical laboratories in British Columbia, Canada","authors":"Roy Yu-Wei Chen ,&nbsp;Junyan Shi","doi":"10.1016/j.clinbiochem.2023.110686","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Clinical laboratories in British Columbia, Canada implemented the CKD-EPI 2009 equation without the race variable for estimated glomerular filtration rate (eGFR) reporting since 2014. As more clinical laboratories adopt the new CKD-EPI 2021 equation, the study aims to compare these two race-free CKD-EPI eGFR equations using the laboratory data from a large tertiary hospital in BC and evaluate the impact on reclassification of eGFR category.</p></div><div><h3>Methods</h3><p>Serum/plasma creatinine results and demographic data were collected from Vancouver General Hospital laboratory. The CKD-EPI 2009 without the race variable and CKD-EPI 2021 equations were computed. eGFR and its distributions were compared and reclassification of eGFR category was assessed across the full cohort and in specific patient populations.</p></div><div><h3>Results</h3><p>The analysis included 58,763 patients. The median age was 57 years, with women comprising 51 % of the population. The median of eGFR changed from 85 to 90 mL/min/1.73 m<sup>2</sup> using the CKD-EPI 2009 equation without the race variable and the CKD-EPI 2021 equation, respectively. The CKD-EPI 2021 equation reclassified 11.86 % of patients, mainly from G3a (45–59 mL/min/1.73 m<sup>2</sup>) to G2 (60–89 mL/min/1.73 m<sup>2</sup>). There was statistical significance between the non-renal and the renal population reclassified from G5 (&lt;15 mL/min/1.73 m<sup>2</sup>) to G4 (15–29 mL/min/1.73 m<sup>2</sup>).</p></div><div><h3>Conclusions</h3><p>Using laboratory data representative of local populations, we observed an overall positive shift to higher eGFR, with 11.86 % of individuals having improved eGFR categories based on the CKD-EPI 2021 equation. This study provides insights into clinical implications at both the individual and population levels. The data-based approach is the first step towards adopting the CKD-EPI 2021 equation within the province.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"123 ","pages":"Article 110686"},"PeriodicalIF":2.5000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S000991202300214X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Clinical laboratories in British Columbia, Canada implemented the CKD-EPI 2009 equation without the race variable for estimated glomerular filtration rate (eGFR) reporting since 2014. As more clinical laboratories adopt the new CKD-EPI 2021 equation, the study aims to compare these two race-free CKD-EPI eGFR equations using the laboratory data from a large tertiary hospital in BC and evaluate the impact on reclassification of eGFR category.

Methods

Serum/plasma creatinine results and demographic data were collected from Vancouver General Hospital laboratory. The CKD-EPI 2009 without the race variable and CKD-EPI 2021 equations were computed. eGFR and its distributions were compared and reclassification of eGFR category was assessed across the full cohort and in specific patient populations.

Results

The analysis included 58,763 patients. The median age was 57 years, with women comprising 51 % of the population. The median of eGFR changed from 85 to 90 mL/min/1.73 m2 using the CKD-EPI 2009 equation without the race variable and the CKD-EPI 2021 equation, respectively. The CKD-EPI 2021 equation reclassified 11.86 % of patients, mainly from G3a (45–59 mL/min/1.73 m2) to G2 (60–89 mL/min/1.73 m2). There was statistical significance between the non-renal and the renal population reclassified from G5 (<15 mL/min/1.73 m2) to G4 (15–29 mL/min/1.73 m2).

Conclusions

Using laboratory data representative of local populations, we observed an overall positive shift to higher eGFR, with 11.86 % of individuals having improved eGFR categories based on the CKD-EPI 2021 equation. This study provides insights into clinical implications at both the individual and population levels. The data-based approach is the first step towards adopting the CKD-EPI 2021 equation within the province.

使用实验室数据评估CKD-EPI 2021肌酐方程:加拿大不列颠哥伦比亚省临床实验室实践变化的考虑
自2014年以来,加拿大不列颠哥伦比亚省的临床实验室在肾小球滤过率(eGFR)估计报告中实施了不含种族变量的CKD-EPI 2009方程。随着越来越多的临床实验室采用新的CKD-EPI 2021方程,本研究旨在使用BC省一家大型三级医院的实验室数据比较这两种无种族CKD-EPI eGFR方程,并评估对eGFR类别重新分类的影响。方法:从温哥华总医院实验室收集血清/血浆肌酐结果和人口统计学数据。计算不含种族变量的CKD-EPI 2009方程和CKD-EPI 2021方程。比较eGFR及其分布,并在整个队列和特定患者群体中评估eGFR类别的重新分类。结果:共纳入58,763例患者。中位年龄为57岁,女性占人口的51%。使用不含种族变量的CKD-EPI 2009方程和CKD-EPI 2021方程,eGFR的中位数分别从85到90 mL/min/1.73 m2变化。CKD-EPI 2021方程将11.86%的患者重新分类,主要从G3a (45-59 ml/min/1.73m2)到G2 (60-89 ml/min/1.73m2)。从G5(2)到G4 (15 ~ 29 mL/min/1.73 m2),非肾组与肾组间差异有统计学意义。结论:利用代表当地人群的实验室数据,我们观察到eGFR总体正向升高,根据CKD-EPI 2021方程,11.86%的个体eGFR类别有所改善。这项研究为个体和人群水平的临床意义提供了见解。基于数据的方法是在省内采用CKD-EPI 2021方程的第一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical biochemistry
Clinical biochemistry 医学-医学实验技术
CiteScore
5.10
自引率
0.00%
发文量
151
审稿时长
25 days
期刊介绍: Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信